Arbutus announces robust hbsag decline data with ab-729 dosed at 60 mg every 8 weeks in chronic hepatitis b subjects

Repeat dosing of 60 mg ab-729 every 8 weeks resulted in mean hbsag declines of –1.37 log10 (n=6) comparable to ab-729 dosed every 4 weeks ( –1.44 log10, n=7, p

ABUS Ratings Summary

ABUS Quant Ranking